Alto Neuroscience Q1 FY26 net loss widens to $26.2 million; R&D expenses more than doubled to $20.3 million

Alto Neuroscience

Alto Neuroscience

ANRO

0.00
  • Alto Neuroscience posted a net loss of USD 26.2 million for quarter ended March 31, 2026, widening from a net loss of USD 15.2 million a year earlier.
  • R&D expenses more than doubled to USD 20.3 million, while G&A expenses rose to USD 6.8 million.
  • Cash, cash equivalents, restricted cash climbed to USD 264.2 million from USD 177.0 million as of Dec. 31, 2025, reflecting net proceeds of about USD 115 million from a March PIPE.
  • Phase 2b trial of ALTO-207 in treatment-resistant depression was initiated in April; Phase 3 initiation remains targeted for early 2027, with Phase 2b topline data guided for 2H 2027.
  • Cash runway expected to extend through 2029, including a planned Phase 3 trial and potential NDA submission for ALTO-207.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001999480-26-000011), on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.